Organon Has Expanded Its Agreement With Eli Lilly To Become The Sole Distributor And Promoter Of The Migraine Medicine Emgality (Galcanezumab) In Additional Markets, Total Consideration To Be Paid To Lilly Includes An Upfront Payment Of $22.5M As Well...
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.